102 related articles for article (PubMed ID: 18855573)
1. A potent anti-carcinoma and anti-acute myeloblastic leukemia agent, AG490.
Caceres-Cortes JR
Anticancer Agents Med Chem; 2008 Oct; 8(7):717-22. PubMed ID: 18855573
[TBL] [Abstract][Full Text] [Related]
2. JAK2 tyrosine kinase inhibitor AG490 suppresses cell growth and invasion of gallbladder cancer cells via inhibition of JAK2/STAT3 signaling.
Fu LX; Lian QW; Pan JD; Xu ZL; Zhou TM; Ye B
J Biol Regul Homeost Agents; 2017; 31(1):51-58. PubMed ID: 28337870
[TBL] [Abstract][Full Text] [Related]
3. Novel small molecular inhibitors disrupt the JAK/STAT3 and FAK signaling pathways and exhibit a potent antitumor activity in glioma cells.
Swiatek-Machado K; Mieczkowski J; Ellert-Miklaszewska A; Swierk P; Fokt I; Szymanski S; Skora S; Szeja W; Grynkiewicz G; Lesyng B; Priebe W; Kaminska B
Cancer Biol Ther; 2012 Jun; 13(8):657-70. PubMed ID: 22555804
[TBL] [Abstract][Full Text] [Related]
4. Tyrphostin B42 inhibits IL-12-induced tyrosine phosphorylation and activation of Janus kinase-2 and prevents experimental allergic encephalomyelitis.
Bright JJ; Du C; Sriram S
J Immunol; 1999 May; 162(10):6255-62. PubMed ID: 10229872
[TBL] [Abstract][Full Text] [Related]
5. JAK2 tyrosine kinase inhibitor tyrphostin AG490 downregulates the mitogen-activated protein kinase (MAPK) and signal transducer and activator of transcription (STAT) pathways and induces apoptosis in myeloma cells.
De Vos J; Jourdan M; Tarte K; Jasmin C; Klein B
Br J Haematol; 2000 Jun; 109(4):823-8. PubMed ID: 10929036
[TBL] [Abstract][Full Text] [Related]
6. Concomitant inactivation of the epidermal growth factor receptor, phosphatidylinositol 3-kinase/Akt and Janus tyrosine kinase 2/signal transducer and activator of transcription 3 signalling pathways in cardiotoxin III-treated A549 cells.
Su JC; Lin KL; Chien CM; Chuang PW; Chang LS; Lin SR
Clin Exp Pharmacol Physiol; 2010 Aug; 37(8):833-40. PubMed ID: 20456425
[TBL] [Abstract][Full Text] [Related]
7. Abrogation of constitutive STAT3 activity sensitizes human hepatoma cells to TRAIL-mediated apoptosis.
Kusaba M; Nakao K; Goto T; Nishimura D; Kawashimo H; Shibata H; Motoyoshi Y; Taura N; Ichikawa T; Hamasaki K; Eguchi K
J Hepatol; 2007 Oct; 47(4):546-55. PubMed ID: 17602782
[TBL] [Abstract][Full Text] [Related]
8. Effects of a JAK inhibitor, AG490, on proliferation and apoptosis of human nasopharyngeal carcinoma cell line CNE-2Z.
Wu MH; Chen XY; Cai KR
Ai Zheng; 2009 Jan; 28(1):24-8. PubMed ID: 19448411
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of constitutive STAT3 activity sensitizes resistant non-Hodgkin's lymphoma and multiple myeloma to chemotherapeutic drug-mediated apoptosis.
Alas S; Bonavida B
Clin Cancer Res; 2003 Jan; 9(1):316-26. PubMed ID: 12538484
[TBL] [Abstract][Full Text] [Related]
10. Analysis of signal transducer and activator of transcription 3 (STAT3) in gastrointestinal stromal tumors.
Paner GP; Silberman S; Hartman G; Micetich KC; Aranha GV; Alkan S
Anticancer Res; 2003; 23(3B):2253-60. PubMed ID: 12894500
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of the signal transducers and activators of transcription (STAT) 3 signalling pathway by AG490 in laryngeal carcinoma cells.
Zhang H; Zhang D; Luan X; Xie G; Pan X
J Int Med Res; 2010; 38(5):1673-81. PubMed ID: 21309481
[TBL] [Abstract][Full Text] [Related]
12. Pterostilbene exerts antitumor activity against human osteosarcoma cells by inhibiting the JAK2/STAT3 signaling pathway.
Liu Y; Wang L; Wu Y; Lv C; Li X; Cao X; Yang M; Feng D; Luo Z
Toxicology; 2013 Feb; 304():120-31. PubMed ID: 23313376
[TBL] [Abstract][Full Text] [Related]
13. AG490, a Jak2 inhibitor, suppressed the progression of murine ovarian cancer.
Kobayashi A; Tanizaki Y; Kimura A; Ishida Y; Nosaka M; Toujima S; Kuninaka Y; Minami S; Ino K; Kondo T
Eur J Pharmacol; 2015 Nov; 766():63-75. PubMed ID: 26410360
[TBL] [Abstract][Full Text] [Related]
14. A novel inhibitor of the STAT3 pathway induces apoptosis in malignant glioma cells both in vitro and in vivo.
Iwamaru A; Szymanski S; Iwado E; Aoki H; Yokoyama T; Fokt I; Hess K; Conrad C; Madden T; Sawaya R; Kondo S; Priebe W; Kondo Y
Oncogene; 2007 Apr; 26(17):2435-44. PubMed ID: 17043651
[TBL] [Abstract][Full Text] [Related]
15. Preclinical characterization of INCB053914, a novel pan-PIM kinase inhibitor, alone and in combination with anticancer agents, in models of hematologic malignancies.
Koblish H; Li YL; Shin N; Hall L; Wang Q; Wang K; Covington M; Marando C; Bowman K; Boer J; Burke K; Wynn R; Margulis A; Reuther GW; Lambert QT; Dostalik Roman V; Zhang K; Feng H; Xue CB; Diamond S; Hollis G; Yeleswaram S; Yao W; Huber R; Vaddi K; Scherle P
PLoS One; 2018; 13(6):e0199108. PubMed ID: 29927999
[TBL] [Abstract][Full Text] [Related]
16. The JAK2 inhibitor AG490 predominantly abrogates the growth of human B-precursor leukemic cells with 11q23 translocation or Philadelphia chromosome.
Miyamoto N; Sugita K; Goi K; Inukai T; Lijima K; Tezuka T; Kojika S; Nakamura M; Kagami K; Nakazawa S
Leukemia; 2001 Nov; 15(11):1758-68. PubMed ID: 11681418
[TBL] [Abstract][Full Text] [Related]
17. Constitutive activation of STAT transcription factors in acute myelogenous leukemia.
Spiekermann K; Biethahn S; Wilde S; Hiddemann W; Alves F
Eur J Haematol; 2001 Aug; 67(2):63-71. PubMed ID: 11722592
[TBL] [Abstract][Full Text] [Related]
18. WP1066 disrupts Janus kinase-2 and induces caspase-dependent apoptosis in acute myelogenous leukemia cells.
Ferrajoli A; Faderl S; Van Q; Koch P; Harris D; Liu Z; Hazan-Halevy I; Wang Y; Kantarjian HM; Priebe W; Estrov Z
Cancer Res; 2007 Dec; 67(23):11291-9. PubMed ID: 18056455
[TBL] [Abstract][Full Text] [Related]
19. The functional role of the JAK-STAT pathway in post-infarction remodeling.
El-Adawi H; Deng L; Tramontano A; Smith S; Mascareno E; Ganguly K; Castillo R; El-Sherif N
Cardiovasc Res; 2003 Jan; 57(1):129-38. PubMed ID: 12504822
[TBL] [Abstract][Full Text] [Related]
20. Tyrosine kinase inhibitor AG490 inhibits the proliferation and migration and disrupts actin organization of cancer cells.
Kamran MZ; Patil P; Shirsath K; Gude RP
J Environ Pathol Toxicol Oncol; 2013; 32(4):361-71. PubMed ID: 24579787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]